Molecular LogiX is a drug discovery company in Houston, Texas. We use our proprietary “Dominant Negative Ligand Drug Discovery System” to produce new drug candidates based on well-characterized, naturally occurring human proteins.

Our most advanced compound is a Pan-HER Dominant Negative Ligand (DNL) that targets the Human Epidermal Growth Factor Receptor (HER/ErbB) family of receptors.  The HER/ErbB axis plays a central role in the progression of many human cancers.  This complex system is modulated by at least 12 different circulating ligands, each with its own specificity for binding and activating a subset of the HER family of receptors.  We re-engineered Epidermal Growth Factor (EGF) to create a new Pan-HER antagonist that inhibits the activity of all the ligand-dependent HER family receptors.

This Pan-HER Dominant Negative Ligand (DNL) binds with nM affinity, inhibits the EGF-dependent phosphorylation of EGFR and the HRG-dependent phosphorylation of HER3 and HER4, is not internalized by HER receptor expressing cells and inhibits the internalization of EGF and heregulin by these cells.  The Pan-HER DNL inhibits the growth of HER-ligand dependent tumor cell lines including the trastuzumab-resistant tumor cell line MDA-MB-175 and has significant therapeutic potential, especially as an agent to treat tumors that have acquired resistance to conventional RTK inhibitors and monoclonal antibodies.

MLX’s DNLs are proprietary variants of clinically relevant human proteins. We use advanced structural and experimental tools to re-design these proteins to create potent targeted antagonists that interfere with the ligand-dependent progression of disease. We expect our first lead, MLX052001, which interferes with the entire “HER axis,” to be effective against a number of tumor types including difficult-to-treat cancers like pancreatic and lung. We have a pipeline of additional compounds that target other commercially validated targets.

We collaborate with leading scientists and clinicians at the Texas Medical Center and elsewhere in order to minimize the time from “bench to bedside.”

The Company has been financed through seed-stage investments from BCM Technologies (the venture subsidiary of Baylor College of Medicine), SBIR grants from the National Cancer Institute, and by an award from the Texas Emerging Technology Fund.  The Company is evaluating strategic alliances and additional early-stage  investors in order to accelerate the preclinical development of our lead compound and support further work on compounds in our pipeline.